MTOR and capillary leak syndrome: For instance, capillary leak syndrome by bortezomib administration [22] and high frequency of grade 1–2 ILD by mammalian target of rapamycin (mTOR) inhibitor [23] are examples of specific ILD features related to molecularly targeted drugs [16].